Minhyung Kim1, Daniel T Fisher1, Colin A Powers2, Emmanuel M Gabriel2, Alexis M Korman3, Sandra Sexton4, Andrei V Gudkov5, Joseph J Skitzki6. 1. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York; Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York. 2. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York. 3. Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York. 4. Department of Laboratory Animal Resources, Roswell Park Cancer Institute, Buffalo, New York. 5. Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York. 6. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York; Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York. Electronic address: joseph.skitzki@roswellpark.org.
Abstract
BACKGROUND: The liver has unique anatomy in that most blood flow to normal hepatocytes is derived from the portal venous system, whereas liver tumors obtain their nutrient blood supply exclusively from the hepatic artery. The focused arterial delivery of anticancer agents to liver tumors has been performed for decades; however, preclinical models to standardize drug regimens and examine novel agents have been lacking. The purpose of this study was to establish preclinical hepatic artery infusion (HAI) models in a mouse and to evaluate the safety and delivery capability of the models. MATERIAL AND METHODS: C57BL/6 and BALB/c mice were used to develop models of HAI via the hepatic artery (HA), superior pancreaticoduodenal artery (SPDA), or lienogastric artery (LGA). Success rates, distribution of perfusion, and associated morbidity and mortality were analyzed between groups. RESULTS: All three models were feasible and reproducible in mice, and there was no statistical difference on body weight change between models. The HA model had a 13.3% mortality from acute liver failure, and the SPDA model demonstrated duodenal and pancreatic toxicity. SPDA and LGA routes had the highest success rates (96.7% and 91.4%, respectively) with low mortality, better drug delivery, and preserved physiologic liver function compared with the HA model. CONCLUSIONS: The optimal route of HAI was mouse breed specific; SPDA access in BALB/c mice, and the LGA access in C57BL/6 mice. The described techniques serve as a reproducible platform for the identification and characterization of therapeutics for diverse metastatic liver tumors.
BACKGROUND: The liver has unique anatomy in that most blood flow to normal hepatocytes is derived from the portal venous system, whereas liver tumors obtain their nutrient blood supply exclusively from the hepatic artery. The focused arterial delivery of anticancer agents to liver tumorshas been performed for decades; however, preclinical models to standardize drug regimens and examine novel agents have been lacking. The purpose of this study was to establish preclinical hepatic artery infusion (HAI) models in a mouse and to evaluate the safety and delivery capability of the models. MATERIAL AND METHODS: C57BL/6 and BALB/c mice were used to develop models of HAI via the hepatic artery (HA), superior pancreaticoduodenal artery (SPDA), or lienogastric artery (LGA). Success rates, distribution of perfusion, and associated morbidity and mortality were analyzed between groups. RESULTS: All three models were feasible and reproducible in mice, and there was no statistical difference on body weight change between models. The HA model had a 13.3% mortality from acute liver failure, and the SPDA model demonstrated duodenal and pancreatic toxicity. SPDA and LGA routes had the highest success rates (96.7% and 91.4%, respectively) with low mortality, better drug delivery, and preserved physiologic liver function compared with the HA model. CONCLUSIONS: The optimal route of HAI was mouse breed specific; SPDA access in BALB/c mice, and the LGA access in C57BL/6 mice. The described techniques serve as a reproducible platform for the identification and characterization of therapeutics for diverse metastatic liver tumors.
Authors: Kevin C Soares; Kelly Foley; Kelly Olino; Ashley Leubner; Skye C Mayo; Ajay Jain; Elizabeth Jaffee; Richard D Schulick; Kiyoshi Yoshimura; Barish Edil; Lei Zheng Journal: J Vis Exp Date: 2014-09-27 Impact factor: 1.355
Authors: Gena P Kanas; Aliki Taylor; John N Primrose; Wendy J Langeberg; Michael A Kelsh; Fionna S Mowat; Dominik D Alexander; Michael A Choti; Graeme Poston Journal: Clin Epidemiol Date: 2012-11-07 Impact factor: 4.790
Authors: Minhyung Kim; Colin A Powers; Leslie I Curtin; Daniel T Fisher; Sandra Sexton; Katerina V Gurova; Joseph J Skitzki; Renuka V Iyer Journal: J Surg Res Date: 2020-03-03 Impact factor: 2.192
Authors: Yuzhu Wang; Junjie Li; Indhumathy Subramaniyan; Goncalo Dias do Vale; Jaideep Chaudhary; Arnida Anwar; Mary Wight-Carter; Jeffrey G McDonald; William C Putnam; Tao Qin; Hongwei Zhang; Ian R Corbin Journal: Toxicol Appl Pharmacol Date: 2020-05-15 Impact factor: 4.219
Authors: Degang Kong; Tao Jiang; Jian Liu; Xinyi Jiang; Bei Liu; Cheng Lou; Baobing Zhao; Steven L Carroll; Gong Feng Journal: Drug Deliv Date: 2020-11-26 Impact factor: 6.419